Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
April 15, 2024 08:00 ET
|
Optimi Health Corp.
Optimi announces completion of three batches of its MDMA API manufactured from raw materials under the Company’s Precursor Licence.
PharmAla Announces Private Placement and Concurrent Debt Settlement
April 10, 2024 16:30 ET
|
PharmAla Biotech
PharmAla Initiates $750,000 Private Placement with concurrent debt settlement, anticipated to close on April 17th 2024
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024 08:58 ET
|
PharmAla Biotech
PharmAla Biotech announces that its Australian Joint Venture, Cortexa, has initiated manufacturing of LaNeo MDMA in Australia.
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract
April 02, 2024 07:30 ET
|
Optimi Health Corp.
Optimi receives Certificate Of Analysis for GMP Natural Psilocybin Extract. Company has also completed the in-house encapsulation of 5mg & 10mg psilocybin.
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
March 28, 2024 07:30 ET
|
Optimi Health Corp.
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024 08:00 ET
|
PharmAla Biotech
PharmAla recieves Allowance from USPTO for its lead drug candidate, a next-generation MDMA composition paving the way for clinical trials
PharmAla Biotech Signs Sale Agreement with Numinus
March 26, 2024 08:55 ET
|
PharmAla Biotech
PharmAla announces binding sales order from Numinus Wellness, as well as a recent presentation of data to the Behaviour, Biology, and Chemistry Conference
Optimi Health to Supply MDMA for Psychedelic Research at Tel Aviv University
March 26, 2024 07:30 ET
|
Optimi Health Corp.
Supply agreement marks Optimi’s first international shipment of research-grade active pharmaceutical ingredient (API) MDMA to Israel
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024 10:20 ET
|
PharmAla Biotech
PharmAla Recieves Notice of Allowance of Patent on Novel MDMA-like Molecule with improved safety, therapeutic range
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024 08:55 ET
|
PharmAla Biotech
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme